Search

Amgen Inc

Chiusa

SettoreSettore sanitario

366.43 -0.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

361.24

Massimo

368.5

Metriche Chiave

By Trading Economics

Entrata

486M

1.8B

Vendite

-1.3B

8.6B

P/E

Media del settore

25.502

62.58

EPS

5.15

Rendimento da dividendi

2.64

Margine di Profitto

21.107

Dipendenti

31,500

EBITDA

-1.2B

3.9B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-1.37% downside

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

2.64%

2.19%

Utili prossimi

4 ago 2026

Prossima data del Dividendo

11 set 2026

Prossima data del' Ex Dividendo

21 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

13B

197B

Apertura precedente

366.6

Chiusura precedente

366.43

Notizie sul Sentiment di mercato

By Acuity

41%

59%

110 / 340 Classifica in Healthcare

Amgen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 lug 2026, 23:46 UTC

Amgen Inc shares are lower in after-market hours, reflecting a modest recovery from earlier losses. No specific news was identified to explain the movement.

20 lug 2026, 19:56 UTC

Social Media

Amgen Inc. shares are lower today, reflecting broader market trends amid geopolitical tensions and inflation concerns. The stock ranks fourth in the SCHD ETF.

17 lug 2026, 20:02 UTC

Macro Event

Amgen Inc. shares are lower during Friday's session, despite a rise in the Michigan Consumer Sentiment Index to 54.4 in July.

16 lug 2026, 18:02 UTC

Amgen Inc. shares are higher today, diverging from broader market declines amid rising crude oil prices and geopolitical tensions. No specific news was identified.

15 lug 2026, 19:16 UTC

Amgen Inc shares are higher Wednesday, reflecting a positive market trend amid investor interest in biotechnology despite geopolitical tensions affecting the bond market.

14 lug 2026, 19:16 UTC

News
Macro Event

Amgen Inc. shares are lower amid pressure from recent product recalls due to quality control issues, impacting its reputation and operational efficiency.

13 lug 2026, 19:46 UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

10 lug 2026, 23:16 UTC

Amgen Inc. shares are higher in after-market trading, remaining near the upper end of their one-month range amid rising U.S. Treasury yields.

9 lug 2026, 23:01 UTC

Amgen Inc shares are trading lower in after-market hours, following unusual trading activity with no specific news identified to explain the decline.

8 lug 2026, 23:21 UTC

Amgen Inc shares are lower in after-market hours, reflecting broader market declines amid geopolitical tensions and a significant drop in the DAX 30 Index.

7 lug 2026, 19:06 UTC

News

Truist Securities raised Amgen's price target to $340, maintaining a Hold rating. Shares are advancing, reflecting positive sentiment and long-term value creation.

6 lug 2026, 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2 lug 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

1 lug 2026, 19:11 UTC

Social Media

Amgen Inc shares are lower amid social media discussions on AI's impact on drug discovery and client platform risk perceptions in the biopharma sector.

29 giu 2026, 19:11 UTC

News

Amgen Inc shares are higher today, supported by a broader market rally and investor confidence from South Korea's $576 billion investment plan in technology.

26 giu 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

25 giu 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, continuing a recent positive trend with four consecutive sessions of gains. No specific news was identified.

24 giu 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 giu 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 giu 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 giu 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 giu 2026, 19:53 UTC

Macro Event

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 giu 2026, 19:22 UTC

News

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 giu 2026, 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 giu 2026, 19:51 UTC

News

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 giu 2026, 23:06 UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 giu 2026, 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 giu 2026, 19:56 UTC

News

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 giu 2026, 20:06 UTC

News

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 giu 2026, 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

Confronto tra pari

Modifica del prezzo

Amgen Inc Previsione

Obiettivo di Prezzo

By TipRanks

-1.37% in calo

Previsioni per 12 mesi

Media 359.17 USD  -1.37%

Alto 427 USD

Basso 300 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amgen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

24 ratings

10

Acquista

13

Mantieni

1

Vendi

Sentiment

By Acuity

110 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat